Pantogar capsules 90 pcs

Pharmacodynamics. The active ingredients of the drug belong to the following therapeutic groups: vitamins, nutritional supplements, amino acids, proteins.

Thiamine nitrate, calcium pantothenate and other vitamins contained in medical yeast are necessary to maintain optimal regulation of metabolism in the body. Insufficient intake of these vitamins by the body causes symptoms of vitamin deficiency.

Keratin is the main component of hair and nails, cystine and 4-aminobenzoic acid are also substances for strengthening hair and nails.

Pantogar helps reduce hair loss caused by various causes, improving the hair structure and increasing its resistance to mechanical and chemical action. Pantogar promotes nail growth and increases their strength.

Pharmacokinetics. No pharmacokinetic studies of Pantogar have been conducted. Vitamins are absorbed in the upper gastrointestinal tract. Amino acid components obtained as a result of keratin hydrolysis, as well as cystine and 4-aminobenzoic acid, are absorbed by passive diffusion and/or through certain transport systems.

Diffuse hair loss (hair loss of unknown causes). Degenerative changes in hair structure (thin, hard, brittle, dull, colorless hair). Hair damage due to exposure to sunlight or ultraviolet radiation. Prevention of gray hair. Nail growth disorders (fragility, delamination, loss of plasticity).

The drug is taken orally during meals, without chewing, with sufficient liquid. Adults are prescribed 1 capsule 3 times a day, children over 12 years old – 1 capsule 1-2 times a day.

The duration of treatment is determined individually. The average duration of treatment is 3-6 months. If necessary, the course of treatment can be extended or repeated.

Children: Due to the lack of sufficient experience in younger children, the drug should not be prescribed to children under 12 years of age.

Hypersensitivity to the components of the drug.

The side effects listed below are classified by system organ class and frequency of occurrence. Frequency categories are: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000) or not known if the frequency cannot be estimated from the available data.

From the nervous system: frequency unknown – headache and dizziness.

From the cardiovascular system: rarely – tachycardia, rapid pulse; frequency unknown – palpitations (increased heartbeat).

On the part of the digestive system: frequency unknown – nausea, vomiting, abdominal pain, flatulence, heartburn, diarrhea.

Skin and subcutaneous tissue disorders: rarely – urticaria, rash, itching; frequency unknown – skin redness.

Immune system disorders: Rare: hypersensitivity reactions such as increased sweating.

If any adverse reactions occur, discontinue use of the drug and consult a doctor.

Use during pregnancy and breastfeeding. The potential risk to humans is unknown. The drug can only be used from the second half of pregnancy if, in the opinion of the doctor, the benefit to the mother outweighs the potential risk to the fetus/child.

The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.

When using drugs containing sulfonamides at the same time, it is necessary to consult a doctor.

Symptoms of overdose are unknown. Treatment is symptomatic.

At a temperature not exceeding 25 °C.